Patient info Open main menu

Trumenba 60 micrograms / dose suspension for injection - Patient leaflet, side effects, dosage

Text from the MHRA, as of · About this document

Medicine status: Prescription only (POM) Details

Medicine strength:
60 micrograms / dose
Contains active substance:

Patient leaflet - Trumenba 60 micrograms / dose suspension for injection

1. What Trumenba is and what it is used for

Trumenba is a vaccine to prevent invasive meningococcal disease, caused by Neisseria meningitidis serogroup B, for use in people 10 years and older. This is a type of bacteria that can cause serious and sometimes life threatening infections such as meningitis (inflammation of the covering of the brain and spinal cord) and sepsis (blood poisoning).

The vaccine contains 2 important components from the surface of the bacteria.

The vaccine works by helping the body to make antibodies (the body’s natural defences) which protect you or your child against this disease.

2. What you need to know before you or your child receives Trumenba

Trumenba should not be given

  • if you or your child are allergic to the active

    substance or any of the other ingredients of this medicine (listed in section 6).

    Warnings and precautions

Talk to your doctor, pharmacist or nurse before vaccination with Trumenba. Tell your doctor, pharmacist or nurse if you or your child: • have a severe infection with a high fever. If this is

the case, then vaccination will be postponed. The presence of a minor infection, such as a cold, should not require postponement of the vaccination, but talk to your doctor first.

  • have a bleeding problem or bruise easily. • have a weakened immune system which may

    prevent you or your child from getting the full benefit from Trumenba.

  • have had any problems after any dose of

    Trumenba such as an allergic reaction or problems with breathing.

Fainting, feeling faint, or other stress-related reactions can occur as a response to any needle injection. Tell your doctor, pharmacist or nurse if you have experienced this kind of reaction previously.

Other medicines and Trumenba

Tell your doctor, pharmacist or nurse if you or your child are using, have recently used or might use any other medicines or have recently received any other vaccine.

Trumenba can be given at the same time as any of the following vaccine components: tetanus, diphtheria, whooping cough (pertussis), poliovirus, papillomavirus, and meningococcal serogroups A, C, W, Y. Administration of Trumenba with vaccines other than those mentioned above, has not been studied. If you receive more than 1 vaccination at the same time it is important that different injection sites are used.

If you take medicines that affect your immune system (such as radiation therapy, corticosteroids, or some types of cancer chemotherapies), you may not get the full benefit of Trumenba.

Pregnancy and breast-feeding

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before Trumenba is given. Your doctor may still recommend that you receive Trumenba if you are at risk of meningococcal disease.

Driving and using machines

Trumenba has no or little influence on the ability to drive and use machines.

However, some of the side effects mentioned under section 4 ‘Possible side effects’ may temporarily affect you. If this occurs, wait until the effects wear off before driving or using machines.

Trumenba contains polysorbate 80 This vaccine contains 0.018 mg of

polysorbate 80 per dose. Polysorbates may cause allergic reactions. Tell your doctor if you or your child has any known allergies.

Trumenba contains sodium

This vaccine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially ‘sodium-free’.

3. How Trumenba is given

Trumenba will be given to you or your child by a doctor, pharmacist or nurse. It will be injected into the upper arm muscle.

It is important to follow the instructions from the doctor, pharmacist or nurse so that you or your child completes the course of injections.

Individuals 10 years and older

  • You or your child will receive 2 injections of the

    vaccine, the second injection is given 6 months after the first injection;

    or

  • You or your child will receive 2 injections of the

    vaccine given at least 1 month apart and a third injection at least 4 months after the second injection.

  • You or your child may be given a booster.

4. Possible side effects

Like all vaccines, this vaccine can cause side effects, although not everybody gets them.

When Trumenba is given to you or your child, the following side effects may occur:

Very common (may affect more than 1 in 10 people)

  • Redness, swelling and pain at injection site
  • Headache
  • Diarrhoea
  • Nausea
  • Muscle pain
  • Joint pain
  • Chills
  • Fatigue

Common (may affect up to 1 in 10 people)

  • Vomiting
  • Fever ≥ 38°C

Not known (frequency cannot be estimated from the available data)

  • Allergic reactions

    Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via Yellow Card Scheme website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Trumenba

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the label and carton after EXP. The expiry date refers to the last day of that month. Store in a refrigerator (2°C-8°C).

Syringes should be stored in the refrigerator horizontally to minimize the re-dispersion time. Do not freeze.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Trumenba contains

One dose (0.5 ml) contains:

Active substances:

Neisseria meningitidis serogroup B fHbp subfamily A1,2,3

60 micrograms Neisseria meningitidis serogroup B fHbp subfamily B1,2,3

60 micrograms 1 Recombinant lipidated fHbp (factor H binding protein)

2 Produced in Escherichia coli cells by recombinant DNA technology

3 Adsorbed on aluminium phosphate (0.25 milligram aluminium per dose)

Other ingredients:

Sodium chloride (see section 2 Trumenba contains sodium), histidine, water for injections, and polysorbate 80 (E433, see section 2 Trumenba contains polysorbate 80).

What Trumenba looks like and contents of the pack

Trumenba is a white suspension for injection, provided in a pre-filled syringe.

Pack sizes of 1, 5, and 10 pre-filled syringes with or without needles.

Not all pack sizes may be marketed.

Marketing Authorisation Holder and Manufacturer

Marketing Authorisation

Manufacturer

Holder:

responsible for batch release:

Pfizer Limited

Ramsgate Road

Pfizer Manufacturing Belgium NV

Sandwich, Kent

CT13 9NJ

Rijksweg 12

United Kingdom

2870 Puurs-Sint-Amands Belgium

For any information about this medicine, please contact:

Medical Information, Pfizer Ltd, Walton Oaks, Dorking Road, Tadworth, Surrey, KT20 7NS.

Telephone 01304 616161.

This leaflet was last revised in 06/2025. Ref: TU 16_0

<..............................................................................> The following information is intended for healthcare

professionals only:

During storage, a white deposit and clear supernatant may be observed.

The vaccine should be visually inspected for particulate matter and discoloration prior to administration. In the event of any foreign particulate matter and/or variation of physical aspect being observed, do not administer the vaccine.

Shake well prior to use to obtain a homogeneous white suspension.

Trumenba is for intramuscular use only. Do not administer intravascularly or subcutaneously. Trumenba must not be mixed with any other vaccines in the same syringe.

When given at the same time with other vaccines Trumenba must be given at separate injection sites. Any unused vaccine or waste material should be disposed of in accordance with local requirements.

About this document

Source: MHRA - Medicines and Healthcare products Regulatory Agency (products.mhra.gov.uk) · Marketing authorisation: PLGB 00057/1649

MHRA data as of 13 October 2026

Found a mistake? Tell us on the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Facts about Trumenba 60 micrograms / dose suspension for injection

Prescription needed? Yes, prescription-only medicine (POM)
Active substance Meningococcal group B vaccine
Strength 60 micrograms / dose
Pharmaceutical form White liquid suspension.
Excipients Sodium Chloride, Histidine, Polysorbate 80 (E433), Water for injections, For adsorbent, see section 2.
Is it available? Listed as available (NHS Dictionary of Medicines and Devices – not a record of current supplies)
Shelf life 5 years.
Storage Store in a refrigerator (2 °C-8 °C).
Syringes should be stored in the refrigerator horizontally to minimize the re-dispersion time.
Do not freeze.
Drug group (ATC) Vaccines
  1. J Antiinfectives for systemic use
    1. J07 Vaccines
      1. J07A Bacterial vaccines
        1. J07AH Meningococcal vaccines
          1. J07AH09 meningococcus B, multicomponent vaccine
Marketing authorisation PLGB 00057/1649 (first authorised 16 April 2025)
Marketing authorisation holder Pfizer Limited

Sources: the MHRA product information (products.mhra.gov.uk) and the NHS Dictionary of Medicines and Devices (dm+d), release 10.1.0 of 12 October 2026, NHS Business Services Authority. Contains public sector information licensed under the Open Government Licence v3.0.